Companies: 10,795·Total market cap: $144.5T
The Pennant Group, Inc.

The Pennant Group, Inc.

PNTGNASDAQHealthcare● Active
$32.01
+$0.30(+0.93%)
Market Cap$1.1B
P/E Ratio
52W High$37.54
52W Low$21.73

The Pennant Group, Inc. (PNTG) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

pntg · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 7 Wall Street analysts in the past 3 months

SellBuy

Buy

7 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
6
Hold
1
Sell
0
Strong Sell
0
Total: 7 · Buy rate: 85.7%

12-Month Price Target

High

$40.00

Consensus

$39.33

+24.0% upside

Low

$38.00

Median: $40 · Last Close: $31.71

The The Pennant Group, Inc. (PNTG) analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month PNTG price target is $39.33, representing +24.0% upside from the current price of $31.71.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $39 (24.0%)

Consensus Target

$39.33

24.0% upside

High Target

$40

26.1%

Low Target

$38

19.8%

Current Price

$31.71

as of today

Based on analyst price targets, the PNTG stock price prediction for the next 12 months ranges from $38 to $40. The consensus PNTG price forecast of $39.33 implies 24.0% upside from the current price of $31.71.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$30.125.00%

1-day model range: $29.95–$30.3. Peak: $30.3 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$52+64.8%
2028$71+123.5%
2029$85+167.3%
2030$94+196.2%
2031+213.7%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%0%50%
7Buy
0Neutral
7Sell
RSI (14)27.6Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PNTG · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$31.01BUY
MA 10$32.55SELL
MA 20$33.96SELL
MA 50$32.03SELL
MA 100$31.67BUY
MA 200$28.93BUY
Current $PNTG · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$31.43BUY
EMA 10$32.23SELL
EMA 20$32.80SELL
EMA 50$32.47SELL
EMA 100$31.49BUY
EMA 200$29.95BUY
Current $PNTG · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
RBC Capital2026-05-08
Maintains
OutperformOutperform
Truist Securities2026-05-08
Maintains
BuyBuy
Wells Fargo2026-05-08
Maintains
OverweightOverweight
Truist Securities2026-04-13
Maintains
BuyBuy
RBC Capital2026-03-02
Maintains
OutperformOutperform
Wells Fargo2026-01-07
Maintains
OverweightOverweight
Truist Securities2025-12-02
Upgrade ↑
HoldBuy
Wells Fargo2025-11-18
Upgrade ↑
Equal WeightOverweight
RBC Capital2025-11-17
Maintains
OutperformOutperform
Stephens & Co.2025-10-09
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on The Pennant Group, Inc. (PNTG) stock. Of the recent 70 rating actions, 5 were upgrades and 2 were downgrades. 7 analysts currently cover PNTG.

Analyst Recommendation Trends

Buy ratings23↑ +1
Hold ratings00
Sell ratings00

PNTG analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$689M

↓ 40.8% YoY

Revenue Next Year

$930M

↑ 34.9% YoY

EPS This Year

$0.94

EPS Next Year

$1.15

↑ 23.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PNTG EPS of $0.94 for the current fiscal year, based on estimates from 4 analysts. The PNTG revenue forecast is $689M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PNTG stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PNTG price target is $39.33 (+24.0% upside), with an analyst consensus of Buy.

The PNTG short-term stock prediction for tomorrow is $30.12 (-5.00%). The PNTG stock price prediction for 2027 estimates an average of $52. The PNTG stock prediction for 2030 projects a range of $88–$100.

The Pennant Group, Inc. trades on NASDAQ under the ticker PNTG. The PNTG stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PNTG forecast · 8 questions

According to 7 Wall Street analysts, the average 12-month PNTG price target is $39.33, with a high forecast of $40.00 and a low of $38.00. The median price target is shown in the chart above when available. This implies +24.0% potential upside from the current price of $31.71.

PNTG price targetWhat is PNTG price targetPNTG analyst price targetPNTG 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.